Lifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue Estimates

Group 1 - Lifecore Biomedical reported a quarterly loss of $0.1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of -11.11% [1] - The company posted revenues of $36.44 million for the quarter ended May 2025, surpassing the Zacks Consensus Estimate by 1.96%, but down from $37.89 million year-over-year [2] - Lifecore Biomedical has surpassed consensus revenue estimates three times over the last four quarters [2] Group 2 - The stock has added about 4% since the beginning of the year, underperforming the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the coming quarter is -$0.29 on revenues of $25.37 million, and -$0.61 on revenues of $132.88 million for the current fiscal year [7] Group 3 - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 41% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Lifecore Biomedical was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock [6]